Envista (NYSE:NVST) PT Lowered to $19.00 at Robert W. Baird

Envista (NYSE:NVST) had its price objective cut by investment analysts at Robert W. Baird from $22.00 to $19.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s target price points to a potential downside of 3.80% from the stock’s current price.

Other research analysts have also issued reports about the company. Leerink Partnrs reissued an “underperform” rating on shares of Envista in a research report on Monday, February 26th. William Blair lowered Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. SVB Leerink started coverage on Envista in a research report on Monday, February 26th. They issued an “underperform” rating and a $19.00 target price for the company. UBS Group started coverage on Envista in a research report on Friday, January 5th. They issued a “neutral” rating and a $26.00 target price for the company. Finally, Morgan Stanley lowered Envista from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $33.00 to $21.00 in a research report on Friday, April 26th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $27.09.

Envista Stock Up 0.4 %

Shares of NVST opened at $19.75 on Thursday. The stock’s 50-day moving average price is $20.80 and its two-hundred day moving average price is $22.59. Envista has a 12 month low of $18.95 and a 12 month high of $38.43. The company has a current ratio of 2.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $3.39 billion, a PE ratio of -32.38, a PEG ratio of 3.72 and a beta of 1.35.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.04). Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business had revenue of $645.60 million during the quarter, compared to the consensus estimate of $638.37 million. During the same period last year, the business posted $0.52 earnings per share. The business’s revenue was down 2.3% on a year-over-year basis. On average, analysts anticipate that Envista will post 1.41 EPS for the current year.

Hedge Funds Weigh In On Envista

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Corbyn Investment Management Inc. MD boosted its stake in shares of Envista by 0.6% in the 4th quarter. Corbyn Investment Management Inc. MD now owns 73,899 shares of the company’s stock worth $1,778,000 after buying an additional 462 shares during the last quarter. Alliance Wealth Advisors LLC UT boosted its stake in shares of Envista by 6.3% in the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 8,295 shares of the company’s stock worth $231,000 after buying an additional 490 shares during the last quarter. Wedge Capital Management L L P NC lifted its stake in Envista by 0.6% in the fourth quarter. Wedge Capital Management L L P NC now owns 102,309 shares of the company’s stock valued at $2,462,000 after purchasing an additional 569 shares during the last quarter. Securian Asset Management Inc. lifted its stake in Envista by 4.3% in the fourth quarter. Securian Asset Management Inc. now owns 14,465 shares of the company’s stock valued at $348,000 after purchasing an additional 590 shares during the last quarter. Finally, Fifth Third Bancorp lifted its stake in Envista by 98.1% in the fourth quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after purchasing an additional 621 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.